Feasibility of ventricular extracellular volume fraction assessing myocardial changes after anthracycline chemotherapy based on CT

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR1900026275

Enrollment

Unknown

Registered

2019-09-28

Start date

2019-11-01

Completion date

Unknown

Last updated

2019-09-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Myocardial injury after chemotherapy

Interventions

Case series:N/A

Eligibility

Sex/Gender

Female

Age

20 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Female breast cancer patients; 2. Postoperative pathology confirmed invasive breast cancer, TNM stage is IIa~IIb; 3. Accept at least 4 cycles of ACT (doxorubicin + cyclophosphamide, sequential Dorsey) Hesai) or EC (epiubicin + cyclophosphamide) regimen chemotherapy; 4. left ventricular ejection fraction (LVEF) >60%, electrocardiogram, troponin T (Trop) Normal; 5. At least one abdominal CT enhancement examination (covering the heart level) from the beginning of chemotherapy to the end of chemotherapy.

Exclusion criteria

Exclusion criteria: (1) Previous history of other cancers; (2) Previously received other anti-tumor treatments; (3) Previous basic medical history such as hypertension and diabetes.

Design outcomes

Primary

Measure	Time frame
extracellular volume;	—

Countries

China

Contacts

Public ContactYonggang Li

The First Affiliated Hospital of Soochow University

liyonggang224@163.com+86 0512-6778-0155

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026